Findings

What do systematic reviews say?

958 questions · 991 findings · 123 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 177 · 17.9%GRADE not reported 25 · 2.5%Very low 230 · 23.2%Low 321 · 32.4%Moderate 185 · 18.7%High 53 · 5.3%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Intravenous vs intramuscular oxytocin · PPH ≥ 500 mL
  Intravenous versus intramuscular prophylactic oxytocin for reducing blood loss in the third stage of labour 2020 · Cochrane Headline outcomes only
  RR 0.78 [0.66, 0.92]
  6 studies · 7731 participants
  High
Direct match · question page
- Intravenous vs intramuscular oxytocin · Blood transfusion
  Intravenous versus intramuscular prophylactic oxytocin for reducing blood loss in the third stage of labour 2020 · Cochrane Headline outcomes only
  RR 0.44 [0.26, 0.77]
  4 studies · 6684 participants
  High
Direct match · question page
- Intravenous vs intramuscular oxytocin · Severe PPH ≥ 1000 mL
  Intravenous versus intramuscular prophylactic oxytocin for reducing blood loss in the third stage of labour 2020 · Cochrane Headline outcomes only
  RR 0.65 [0.39, 1.08]
  4 studies · 6681 participants
  Moderate
Direct match · question page
- Intravenous vs oral cyclophosphamide · Continuing frequently‐relapsing or steroid‐dependent SSNS at 6 months
  Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.4 [0.18, 0.89]
  1 study · 47 participants
  Low
Direct match · question page
- Intravenous vs intramuscular oxytocin · Use of additional uterotonics
  Intravenous versus intramuscular prophylactic oxytocin for reducing blood loss in the third stage of labour 2020 · Cochrane Headline outcomes only
  RR 0.78 [0.49, 1.25]
  6 studies · 7327 participants
  Low

Intravenous vs intramuscular oxytocin

Severe PPH (≥ 1000 mL) · women in the 3rd stage of labour undergoing a vaginal birth.

Intravenous showed no clear difference in severe PPH ≥ 1000 mL compared with intramuscular oxytocin (moderate certainty).

1 finding from 1 review

Intravenous versus intramuscular prophylactic oxytocin for reducing blood loss in the third stage of labour 2020 · Cochrane Headline outcomes only
RR 0.65 [0.39, 1.08]
4 studies · 6681 participants
Moderate

Intravenous vs intramuscular oxytocin

Serious maternal morbidity · women in the 3rd stage of labour undergoing a vaginal birth.

Intravenous showed no clear difference in serious maternal morbidity compared with intramuscular oxytocin (moderate certainty).

1 finding from 1 review

Intravenous versus intramuscular prophylactic oxytocin for reducing blood loss in the third stage of labour 2020 · Cochrane Headline outcomes only
RR 0.47 [0.22, 1]
4 studies · 7028 participants
Moderate

Intravenous vs intramuscular oxytocin

Maternal death · women in the 3rd stage of labour undergoing a vaginal birth.

1 finding from 1 review

Intravenous versus intramuscular prophylactic oxytocin for reducing blood loss in the third stage of labour 2020 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 7028 participants
Very low

Intravenous vs intramuscular oxytocin

Frequency of PPH ≥ 500 mL · women in the 3rd stage of labour undergoing a vaginal birth.

Intravenous leads to lower PPH ≥ 500 mL compared with intramuscular oxytocin (high certainty).

1 finding from 1 review

Intravenous versus intramuscular prophylactic oxytocin for reducing blood loss in the third stage of labour 2020 · Cochrane Headline outcomes only
RR 0.78 [0.66, 0.92]
6 studies · 7731 participants
High

Intravenous vs intramuscular oxytocin

Use of additional uterotonics · women in the 3rd stage of labour undergoing a vaginal birth.

Intravenous showed no clear difference in use of additional uterotonics compared with intramuscular oxytocin (low certainty).

1 finding from 1 review

Intravenous versus intramuscular prophylactic oxytocin for reducing blood loss in the third stage of labour 2020 · Cochrane Headline outcomes only
RR 0.78 [0.49, 1.25]
6 studies · 7327 participants
Low

Intravenous vs intramuscular oxytocin

Blood transfusion · women in the 3rd stage of labour undergoing a vaginal birth.

Intravenous leads to lower blood transfusion compared with intramuscular oxytocin (high certainty).

1 finding from 1 review

Intravenous versus intramuscular prophylactic oxytocin for reducing blood loss in the third stage of labour 2020 · Cochrane Headline outcomes only
RR 0.44 [0.26, 0.77]
4 studies · 6684 participants
High

Intravenous vs intramuscular oxytocin

Hypotension · women in the 3rd stage of labour undergoing a vaginal birth.

Intravenous showed no clear difference in hypotension compared with intramuscular oxytocin (moderate certainty).

1 finding from 1 review

Intravenous versus intramuscular prophylactic oxytocin for reducing blood loss in the third stage of labour 2020 · Cochrane Headline outcomes only
RR 1.01 [0.88, 1.15]
4 studies · 6468 participants
Moderate

IVIg vs intravenous methylprednisolone

Significant improvement in disability within 6 weeks · people with CIDP

Intravenous immunoglobulin showed no clear difference in significant improvement in disability within 6 weeks compared with intravenous methylprednisolone (moderate certainty).

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
RR 1.46 [0.4, 5.38]
1 study · 45 participants
Moderate

IVIg vs intravenous methylprednisolone

Change in mean disability score on Rankin scale · people with CIDP

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Moderate

IVIg vs intravenous methylprednisolone

Change in mean disability score at 24 weeks or later · people with CIDP

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Moderate

IVIg vs intravenous methylprednisolone

Serious adverse events · people with CIDP

Intravenous immunoglobulin showed no clear difference in serious adverse events compared with intravenous methylprednisolone (moderate certainty).

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
RR 4.4 [0.22, 86.78]
1 study · 45 participants
Moderate

Intravenous vs oral cyclophosphamide

Clinical relapse · SSNS in children

Intravenous may leads to lower relapse at 6 months compared with oral cyclophosphamide (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.54 [0.34, 0.88]
2 studies · 83 participants
Low

Intravenous vs oral cyclophosphamide

Continuing frequently relapsing or steroid‐dependent SSNS at 6 months · SSNS in children

Intravenous may leads to lower continuing frequently‐relapsing or steroid‐dependent SSNS at 6 months compared with oral cyclophosphamide (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.4 [0.18, 0.89]
1 study · 47 participants
Low

Intravenous vs oral cyclophosphamide

Relapse · SSNS in children

Intravenous showed no clear difference in relapse at end of study compared with oral cyclophosphamide (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.99 [0.76, 1.29]
2 studies · 83 participants
Low

Intravenous vs oral cyclophosphamide

Mean relapse rate/patient/month · SSNS in children

The review found no eligible studies for this question.

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intravenous vs oral cyclophosphamide

Adverse effects: leucopenia · SSNS in children

Intravenous showed no clear difference in adverse events: leucopenia compared with oral cyclophosphamide (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.37 [0.09, 1.51]
2 studies · 83 participants
Low

Intravenous vs oral cyclophosphamide

Adverse events: hair loss · SSNS in children

Intravenous showed no clear difference in adverse events: hair loss compared with oral cyclophosphamide (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.19 [0.04, 1.03]
2 studies · 83 participants
Low

Intravenous vs oral cyclophosphamide

Adverse events: all infections · SSNS in children

Intravenous may leads to lower adverse events: all infections compared with oral cyclophosphamide (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.14 [0.03, 0.72]
2 studies · 83 participants
Low

Intravenous vs oral cyclophosphamide

Adverse event nausea and vomiting (0 to 24 hours) · SSNS in children

It is very uncertain whether intravenous changes adverse events: nausea and vomiting compared with oral cyclophosphamide (very low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 4.07 [0.21, 80.51]
1 study · 47 participants
Very low

Intravenous vs intraosseous route

Insertion failures · adults or children requiring fluid delivered by a parenteral route (one study testing insertion and the volume of fluid delivered in…

Intravenous may leads to higher insertion failures compared with intraosseous route (low certainty).

1 finding from 1 review

Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease 2015 · Cochrane Headline outcomes only
RR 3.89 [2.39, 6.33]
2 studies · 242 participants
Low